Gilde has invested in Pharmaline, based in Oldenzaal the Netherlands. Pharmaline is specialized in large scale pharmaceutical compounding. The company is one of the few Dutch players whose facilities and production processes are structured to comply with the guidelines of the Dutch Health Care Inspectorate (IGZ) and Good Manufacturing Practice (GMP).
The external pharmaceutical compounding market is a relatively new niche market in the Netherlands and accounts for approximately 5% of all prescribed drugs in public pharmacies. This market came into existence around 2008. At that time, regulatory pressure forced pharmacies to increase efficiency and to further professionalize the pharmacy value chain. Since 2009, Pharmaline has been at the forefront to develop this new market segment and the company is taking the lead in its professionalization by offering pharmacies a unique and high quality outsourcing opportunity of the full range of outsourced pharmacy preparations. The company is growing rapidly and currently serves about 20% of all public pharmacies in the Netherlands.
The investment team of Gilde Healthcare Services is well versed in this market and sees ample growth opportunities for the company. The Gilde team actively supports the management of the company in expanding the organization and strengthening its market position.
Jan Verwaal, managing director of Pharmaline, comments enthusiastically:
“I am very pleased that Gilde joins us as a new shareholder and I am confident that with the valuable knowledge, experience and capital of Gilde, Pharmaline will flourish in the years to come.”
Jasper van Gorp, partner at Gilde adds:
“Currently, the market for pharmaceutical compounding is professionalizing rapidly, Pharmaline perfectly anticipates to this trend, which provides huge opportunities. We are excited about our partnership with Pharmaline and are confident about the continued success of the company.”